Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FH-WT1-E50 TCR T cells
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FH-WT1-E50 TCR T cells is an autologous, T-cell receptor (TCR) engineered T-cell therapy developed by the Fred Hutchinson Cancer Center. The product consists of both CD4+ and CD8+ T cells genetically modified to express a specific TCR that recognizes the Wilms Tumor 1 (WT1) antigen in the context of HLA-A*02:01. A unique feature of this therapy is the co-expression of the CD8 alpha/beta (CD8ab) coreceptor, which is intended to enhance the functional avidity and cytotoxic potential of the CD4+ T-cell subset against MHC class I-restricted targets. It is currently being evaluated in Phase I clinical trials for the treatment of patients with minimal residual disease (MRD) positive acute myeloid leukemia (AML), often administered following lymphodepletion and in combination with azacitidine to promote antigen expression and T-cell persistence.
- Other names
- autologous HLA-A*02:01-restricted CD4+/CD8+ anti-WT1 TCR/CD8ab-expressing T-cellsWT1-specific TCR T cellsWT-1-specific TCR T cellsWT 1-specific TCR T cells
02
Targets
Wilms' tumor 1 protein-derived peptide-HLA class I complex (WT1-HLA complex)
Beyond the preview
Go deeper on FH-WT1-E50 TCR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FH-WT1-E50 TCR T cells.